STUDY OF THE ACUTE TOXICITY AND COMBINED ACTION OF THE PESTICIDES ACREX AND ACTELIC

No abstrac

PHOSPHATE CRYSTALLURIA IN VARIOUS FORMS OF UROLITHIASIS AND POSSIBILITIES OF ITS PROGNOSTICATION IN PATIENTS WITH PHOSPHATE STONES

Purpose. Definition of types of crystalluria in various forms of urolithiasis and biochemical signs of phosphate crystals in the urine, while phosphate urolithiasis (infectious origin).Patients and methods. The study involved 144 patients with recurrent urolithiasis — 75 women and 69 men. Of these, 46 — diagnosed calculi with uric acid, 44 — calcium oxalate or mixed with a prevalence of calcium oxalate, in 54 — phosphate rocks (carbonate-apatite and/or struvite). The age of patients ranged from 21 to 74 years. 93 people have been under long-term, within 2–15 years, outpatient observation. The examination included the collection of anamnesis, general and microbiological analysis of urine, biochemical blood serum and urine on 10 indicators, reflecting renal function, state of the protein, water and electrolyte metabolism, uric acid metabolism, the chemical composition of the stone analysis.Results. It was found that in patients with calcium oxalate stones phosphaturia has been diagnosed in 2% of cases. And, along with calcium phosphate crystals they had oxalate crystals. In patients with phosphate urolithiasis phosphaturia observed in 96% of patients, in two patients (4%) they determined except phosphates also oxalate salt in urine sediment. Patients with phosphate urolithiasis at occurrence of phosphate crystalluria have metabolic state changes: increased serum uric acid concentration from 0.322 ± 0.009 to 0.367 ± 0.018 mmol/l daily renal excretion of inorganic phosphate 23.94 ± 2.93 mmol/day to 32.12 ± 4.39 mmol/day, and reduced total calcium content in urine 6.61 ± 0.94 mmol/day to 3.37 ± 0.89 mmol/day. The results led to the following conclusion.Conclusion. Biochemical signs of occurrence of phosphate crystalluria in patients with stones of infectious origin can be: the approaching level of excretion in the urine of inorganic phosphates to 32,12 ± 4,39 mmol/day, serum uric acid concentration to 0,367 ± 0,018 mmol/l, and the total content of calcium in the urine to 3.37 ± 0.89 mmol/da

Superconductivity, Electron Paramagnetic Resonance, and Raman Scattering Studies of Heterofullerides with Cs and Mg

In the present study, the results of investigation of physical properties of heterofullerides A3−xMxC60 (A=K, Rb, Cs, M=Be, Mg, Ca, Al, Fe, Tl, x=1,2); as well as RbCsTlC60, KCsTlC60, and KMg2C60 are described. All of the fullerides were synthesized by the exchange reactions of alkaline fullerides with anhydrous metal halides. Superconductivity was found in RbCsTlC60 and KCsTlC60

THROMBOLYTIC THERAPY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

It is reported that the implementation in clinical practice thrombolytic (fibrinolytic) therapy resulted inmortality reduction during firstmonth after myocardial infarction from 17-18% to 5-8%. Different details of this therapy are considered: terms of thrombolysis since the beginning of myocardial infarction, alternative methods of coronary blood flow recovery , indications and contraindications, complications and side effects, estimation of thrombolysis efficacy. Fibrin-selective and fibrin-non-selective drugs are presented. Different fibrinolytics are described: streptokinase, anistreplase, alteplase, reteplase, tenekteplase. The results of large randomized clinical trials devoted to fibrinolytic therapy of myocardial infarction are analyzed: GISSI, ISSIS, TIMI, GUSTO, INJECT, ASSENT. The possibility to increase in efficacy and safety of fibrinolytics by their combination with acetylsalicylic acid, IIb/IIIa receptor inhibitors and heparins are discussed

High-Q trenched aluminum coplanar resonators with an ultrasonic edge microcutting for superconducting quantum devices

Dielectric losses are one of the key factors limiting the coherence of superconducting qubits. The impact of materials and fabrication steps on dielectric losses can be evaluated using coplanar waveguide (CPW) microwave resonators. Here, we report on superconducting CPW microwave resonators with internal quality factors systematically exceeding 5x106 at high powers and 2x106 (with the best value of 4.4x106) at low power. Such performance is demonstrated for 100-nm-thick aluminum resonators with 7-10.5 um center trace on high-resistivity silicon substrates commonly used in quantum Josephson junction circuits. We investigate internal quality factors of the resonators with both dry and wet aluminum etching, as well as deep and isotropic reactive ion etching of silicon substrate. Josephson junction compatible CPW resonators fabrication process with both airbridges and silicon substrate etching is proposed. Finally, we demonstrate the effect of airbridges positions and extra process steps on the overall dielectric losses. The best quality fa ctors are obtained for the wet etched aluminum resonators and isotropically removed substrate with the proposed ultrasonic metal edge microcutting.Comment: 6 pages, 2 figure

Electronic structure and luminescence properties of Ca2Ge7O16:Dy3+

The present report represents an overview of the results of a combined experimental-computational study of electronic structure, thermoluminescence (TL) and afterglow properties of Ca2Ge7O16:Dy3+ synthesized for the first time. Afterglow curves of Ca2Ge7O16:Dy3+ at 575 nm showing persistent luminescence have been described in Becquerel law. The TL measurements reveal at least one TL band at 326 K and two luminescence bands at 475 and 535 nm. Persistent luminescence in Ca2Ge7O16:Dy3+ originates from relatively shallow charge traps with high probability of charge carriers recapture. The model of energy processes, configurations of traps and luminescence centers has been proposed with the aid of ab initio calculations performed using the LCAO approximation and several hybrid functionals

НОВЫЕ ПЕРСПЕКТИВЫ АНТИТРОМБОТИЧЕСКОЙ ТЕРАПИИ У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ, ПЕРЕНЕСШИХ СТЕНТИРОВАНИЕ КОРОНАРНЫХ АРТЕРИЙ: ВОЗМОЖНОСТИ ДАБИГАТРАНА

After percutaneous coronary intervention, patients receive double antiplatelet therapy for several months, which includes acetylsalicylic acid and a P2Y12 receptor inhibitor. In most cases, managing the patients with the atrial fibrillation requires adding an anticoagulant drug to the antiplatelet therapy — triple antithrombotic therapy. The rejection of triple therapy in favour of the administration of an anticoagulant and only one antiaggregant is a prospective line of reducing the risk of bleeding in these patients. The number of studies evaluating the effectiveness and safety of such therapy remains limited, and the guidelines for anticoagulant therapy are largely based on the studies of only "stable" patients with atrial fibrillation and on the results of registers, i.e. data of “real-life” clinical practice. The RE-DUAL PCI study showed that the administration of dabigatran in combination with the P2Y12 receptor inhibitor in patients with atrial fibrillation after percutaneous coronary intervention is much safer and no less effective than the classical triple therapy. A special feature of the study was the evaluation of the effectiveness and safety of two doses of dabigatran, each of which was approved for stroke prevention. This provides clinicians with additional options for treating patients with atrial fibrillation after percutaneous coronary intervention.После проведения чрескожного коронарного вмешательства пациентам в течение нескольких месяцев проводится двойная антиагрегантная терапия, в состав которой входит ацетилсалициловая кислота и блокатор P2Y12-рецепторов. Наличие фибрилляции предсердий у этих пациентов в большинстве случаев обуславливает необходимость назначения в дополнение к антиагрегантной терапии еще и антикоагулянтного препарата, то есть проведение тройной антитромботической терапии. Перспективным направлением снижения риска развития кровотечений у таких пациентов является отказ от тройной терапии в пользу назначения антикоагулянта и только одного антиагреганта. Количество исследований, оценивающих эффективность и безопасность такой терапии, остается ограниченным, и рекомендации относительно использования антикоагулянтной терапии во многом основаны на исследованиях только «стабильных» больных с фибрилляцией предсердий и на результатах регистров — данных «реальной практики». Результаты исследования RE-DUAL PCI показали, что назначение дабигатрана в сочетании с блокатором P2Y12-рецепторов пациентам с фибрилляцией предсердий после чрескожного коронарного вмешательства, в сравнении с традиционной тройной терапией, значительно безопаснее и не менее эффективно.Особенностью исследования стала оценка эффективности и безопасности двух доз дабигатрана, каждая из которых утверждена для профилактики инсульта, что предоставляет клиницистам дополнительные возможности лечения пациентов с фибрилляцией предсердий после чрескожного коронарного вмешательства

Optimization of pathogenetic therapy of viral diarrhea in young children

The article presents the results of observations in 60 patients aged from 6 months to 1 year (breastfeeding and mixed feeding) with acute viral gastroenteritis and clinical manifestations of lactase deficiency. In the experimental group (n = 30) all children received both Laktazar and etiotropic, detoxification and rehydration therapy from the first days of treatment; in the control group (n = 30) Laktazar was not prescribed. We compared the results of treatment and showed clinical benefit of Laktazar: the average duration of watery diarrhea in the experimental group was 4.8 days while in the control group it was 6.4 days (p <0.05).В статье представлены результаты наблюдения за 60 больными в возрасте с 6 месяцев до 1 года, находящихся на естественном и смешанном вскармливании, с клиникой острого вирусного гастроэнтерита и клиническими проявлениями лактазной недостаточности. Сравнивались результаты лечения в опытной группе (n=30), где дети получали Лактазар одновременно с этиотропной, дезинтоксикационной и регидратационной терапией с первых дней лечения, в группе сравнения (n=30) Лактазар не назначался. Показан клинический эффект Лактазара: средняя продолжительность водянистой диареи в исследуемой группе детей составила 4,8 дня, в контрольной группе- 6,4 (р<0,05